Clinical trial
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder
NCT00149799 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00149799 |
|---|---|
| Title | Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder |
| Official title | Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH Rhode Island Hospital |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anxiety Disorders, Somatoform Disorders |
| Intervention type | Drug |
| Interventions | Escitalopram, Placebo |
| Enrollment | 100 |
| Start date | May 1, 2005 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Sep 8, 2005 |
| Last update posted | Dec 5, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: